Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report

详细信息    查看全文

• 作者：Aziza T. Shad ; Jeffrey S. Huo ; Courtney Darcy ; Amal Abu-Ghosh ; Giuseppe Esposito ; Mary-Jo Holuba ; Nancy Robey ; Kenneth R. Cooke ; Heather J. Symons ; Allen R. Chen and Nicolas J. Llosa
• 刊名：Pediatric Blood & Cancer
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：64
• 期：3
• 全文大小：316K
• ISSN：1545-5017

文摘

To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.